Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL325804 | 0.97 | TSHR (0.40) | TSHRMAPTMAPK1LMNATDP1 | |
| SCHEMBL13877207 | 0.94 | TSHR (0.38) | TSHRMAPTMAPK1LMNATDP1 | |
| SCHEMBL8529610 | 0.94 | TSHR (0.38) | TSHRMAPTMAPK1LMNATDP1 | |
| SCHEMBL10486462 | 0.84 | TSHR (0.32) | TSHR | |
| SCHEMBL27532678 | 0.84 | TSHR (0.40) | TSHRMAPTMAPK1LMNAALDH1A1 | |
| SCHEMBL1076490 | 0.83 | TSHR (0.33) | TSHRLMNATDP1ALDH1A1 | |
| SCHEMBL24094055 | 0.82 | — | — | |
| SCHEMBL224194 | 0.82 | — | — | |
| SCHEMBL10100320 | 0.82 | — | — | |
| SCHEMBL15277676 | 0.82 | TSHR (0.31) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2331140-B1 | MULTI-ARM POLYMERIC ALKANOATE CONJUGATES | NEKTAR THERAPEUTICS (US) | 2018-07-04 | — | — | EP | disclosed |
| US-20140088030-A1 | WATER SOLUBLE AND ACTIVABLE PHENOLICS DERIVATIVES WITH DERMOCOSMETIC AND THERAPEUTIC APPLICATIONS AND PROCESS FOR PREPARING SAID DERIVATIVES | LIBRAGEN (FR) | 2014-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140088030-A1 | WATER SOLUBLE AND ACTIVABLE PHENOLICS DERIVATIVES WITH DERMOCOSMETIC AND THERAPEUTIC APPLICATIONS AND PROCESS FOR PREPARING SAID DERIVATIVES | UGGT1, TYR, G6PD | TSHR 4505/4885MAPT 1000/4885MAPK1 484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.